



NEWS RELEASE

CareDx Showcases Leadership in Global Transplantation at ESOT 2021

2021-08-26

CareDx announces the launch of AlloSeq cfDNA Research Service and demonstrates global leadership at ESOT with six abstracts and a symposium

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced a leading presence at the European Society of Organ Transplantation (ESOT) 2021 conference, August 29 to September 1 in Milan, Italy and virtually.

CareDx will showcase leadership in global transplant patient care with six abstracts on AlloSeq cfDNA and the launch of AlloSeq cfDNA Research Service at ESOT. AlloSeq cfDNA is a next generation sequencing based kit to detect donor-derived cfDNA (dd-cfDNA) and can be used locally in a transplant center lab to generate results in less than 24 hours. The newly launched AlloSeq cfDNA Research Service is a solution for centers outside of the US that want to send out dd-cfDNA testing for research use only, and AlloSeq cfDNA will be run out of CareDx's Stockholm site.

CareDx will launch AlloSeq cfDNA Research Service and showcase the latest data on AlloSeq cfDNA at an ESOT symposium titled, "Changing the Transplant Care Paradigm: Advanced Strategies for Allograft Surveillance." The symposium will be held live and streamed virtually on ESOT's platform on Sunday, August 29 from 6:00-7:30 PM CET. Featured speakers include:

- Fritz Diekmann, MD, PhD, Universitat de Barcelona, Hospital Clínic de Barcelona
- Ioannis N. Boletis, MD, PhD, Laiko General Hospital, National & Kapodistrian University of Athens

- Berta Saez-Gimenez, MD, PhD, Hospital Universitari Vall d'Hebrón
- Kiran Khush, MD, Stanford University School of Medicine

AlloSeq cfDNA data will also be presented in six oral presentations or posters at ESOT:

- Pitfalls in the detection of donor-derived cell-free DNA in transplant recipients; Presented by Dr. Jeroen Verhoeven on August 30; 16:45 – 18:15
- Comparing methods for donor-derived cell-free DNA quantification in plasma and urine from kidney and liver transplant recipients; presented by Dr. Nicholas Kueng on August 30; 16:45 – 18:15
- Monitoring kidney graft injury by measuring donor-derived cell-free DNA (dd-cfDNA); Presented by Dr. Emilio Rodrigo on September 1; 08:00 – 09:30
- Prospective evaluation of donor-derived cell-free DNA (dd-cfDNA) in kidney transplant recipients with indication biopsy; Presented by Dr. Louise Benning on September 1; 08:00 – 09:30
- Diagnostic value of donor-derived cell-free DNA to predict antibody-mediated rejection in donor-specific antibody-positive renal allograft recipients; presented by Dr. Katharina Mayer on September 1; 10:00 – 11:30
- Prospective assessment of graft recovery after kidney transplantation by means of donor-derived cell-free DNA; Poster Presentation

“ESOT 2021 is one of the leading conferences for the European organ transplant community to come together and share best practices, and CareDx’s AlloSeq cfDNA solutions will be a focal discussion at the meeting this year,” said Dr. Georg Böhmig, Division of Nephrology and Dialysis at Medical University Vienna, Austria.

“Transplantation is global, and we are excited to see AlloSeq cfDNA presented at ESOT as our solutions for transplant patient care expand internationally. The AlloSeq cfDNA Service through our Stockholm lab will expand our research offerings and support continued innovation and growth in Europe,” said Reg Seeto, CEO at CareDx.

About CareDx

CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release includes forward-looking statements related to CareDx, Inc., including statements regarding CareDx’s launch of AlloSeq cfDNA Research Service (the “Launch”), its participation and leading presence at ESOT with 6 abstracts and a symposium (the “ESOT Presence”), and the potential benefits and results that may be achieved through the Launch and CareDx’s ESOT Presence. These forward-looking statements are based upon

information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that the CareDx does not realize the expected benefits of the Launch and AlloSeq cfDNA Research Service; risks that CareDx fails to showcase the abstracts and the latest data on AlloSeq cfDNA at ESOT as planned; general economic and market factors; and other risks discussed in CareDx's filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed by CareDx with the SEC on February 24, 2021 and other reports that CareDx has filed with the SEC. Any of these may cause CareDx's actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

CONTACTS:

CareDx, Inc.

Sasha King

Chief Marketing Officer

415-287-2393

[sking@caredx.com](mailto:sking@ caredx.com)

Investor Relations

Greg Chodaczek

investor@caredx.com